1. Home
  2. UHG vs CABA Comparison

UHG vs CABA Comparison

Compare UHG & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Homes Group Inc

UHG

United Homes Group Inc

HOLD

Current Price

$1.68

Market Cap

248.7M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.16

Market Cap

212.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHG
CABA
Founded
2004
2017
Country
United States
United States
Employees
N/A
151
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
248.7M
212.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
UHG
CABA
Price
$1.68
$2.16
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
244.4K
1.8M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$418,113,017.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.99
52 Week High
$4.81
$3.67

Technical Indicators

Market Signals
Indicator
UHG
CABA
Relative Strength Index (RSI) 57.17 44.96
Support Level $1.57 $2.08
Resistance Level $1.81 $2.25
Average True Range (ATR) 0.16 0.13
MACD 0.03 -0.00
Stochastic Oscillator 70.04 40.79

Price Performance

Historical Comparison
UHG
CABA

About UHG United Homes Group Inc

United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: